Author’s response to reviews

Title: Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

Authors:

Nicolas Methy (nicolas.methy@u-bourgogne.fr)
Laurent Bedenne (laurent.bedenne@u-bourgogne.fr)
Franck Bonnetain (fbonnetain@cgfl.fr)

Version: 5 Date: 9 June 2010

Author’s response to reviews:

Dear Editor,

Please find the final version of the manuscript. Some corrections were made in the main document and in the Figure 3:

In the results section of the abstract, we replaced “Other unexpected endpoints were metastatic PFS in non operable oesophageal (31%) and pancreatic (44%) cancers” by “An unexpected endpoint was metastatic PFS in non operable oesophageal (31%) and pancreatic (44%) cancers ».

Page 9, we replaced “63” by “63%”.

Page 10, we replaced “For neoadjuvant treatment of rectal cancer” by “For the neoadjuvant treatment of rectal cancer”.

Reference 6 was completed.

In Figure 3, we replaced “aimed at evaluate” by “aimed at evaluating” and “was validated” by “has been validated”.

Yours sincerely,

Nicolas Methy